bezlotoxumab
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Bezlotoxumab is a fully human monoclonal antibody that binds and neutralizes Clostridium difficile toxin B. This analysis…
The MODIFY I/II trials demonstrated that bezlotoxumab, a human monoclonal antibody against Clostridioides difficile toxin B…
Das Darmbakterium Clostridioides difficile ist eine der häufigsten Ursachen nosokomialer Diarrhöen. Die C.-difficile-Infektion…
OBJECTIVE
To review the pharmacology, pharmacokinetics, pharmacodynamics, clinical efficacy, tolerability, dosing, and…
ABSTRACT Introduction: Clostridium difficile infection is a major economic and clinical burden, due to its high frequency of…
Abstract Background CDI in patients with SRI is harder to treat and is associated with higher recurrence. MODIFY I/II found that…
Clostridium difficile ( C. difficile ) infection has become a growing issue facing hospitals in North America and Europe. Each…
n engl j med 376;16 nejm.org April 20, 2017 1596 2. Ollech JE, Shen NT, Crawford CV, Ringel Y. Use of probiotics in prevention…
Background . Treatment guidelines recommend stopping CAs in patients with Clostridium dif fi cile infection (CDI), but this is not…